Peer-reviewed veterinary case report
Liquid biopsy predicts chemo response in dogs with multicentric
By Garnica, Taismara K et al.·Published in Scientific reports·2020·Department of Veterinary Medicine, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Liquid biopsy based on small extracellular vesicles predicts chemotherapy response of canine multicentric lymphomas.
- Species:
- dog
Plain-English summary
A group of dogs with multicentric lymphoma, a common type of blood cancer, underwent a standard chemotherapy treatment called CHOP. Researchers found that by analyzing small particles in the blood called small extracellular vesicles (SEVs), they could predict which dogs would respond well to the treatment and which would not. Out of 19 dogs studied, those that did not respond to chemotherapy had higher levels of SEVs at the start of treatment. This new approach could help veterinarians tailor cancer treatments more effectively for dogs in the future.
People also search for: dog lymphoma treatment · canine chemotherapy response · predicting dog cancer treatment success
Abstract
Lymphoma is the most common type of canine hematological malignancy where the multicentric (cMCL) form accounts for 75% of all cases. The standard treatment is the CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone, where the majority of dogs achieve complete/partial response; however, it is very important to predict non-responsive cases to improve treatment and to develop new targeted therapies. Here we evaluate a liquid biopsy approach based on serum Small Extracellular Vesicles enriched for exosomes (SEVs) to predict cMCL chemotherapy response. Nineteen dogs at the end of the 19-week chemotherapy protocol (8 Complete Response and 11 Progressive Disease) were evaluated for serum SEVs size, concentration and screened for 95 oncomirs. PD patients had higher SEVs concentration at the diagnosis than CR patients (P = 0.034). The ROC curve was significant for SEVs concentration to predict the response to CHOP (AUC = 0.8011, P = 0.0287). A potential molecular signature based on oncomirs from SEVs (caf-miR-205, caf-miR-222, caf-mir-20a and caf-miR-93) is proposed. To the best of our knowledge, this is the first study demonstrating the potential of a liquid biopsy based on SEVs and their miRNAs content to predict the outcome of chemotherapy for canine multicentric lymphomas.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33230132/